Skip to main content

Glycosylation Inhibitors, PKC Inhibitors and Related Interventions Against Complications

  • Chapter
  • 1343 Accesses

Keywords: Hyperglycaemia, advanced glycation end-product, protein kinase C, diabetic complications, receptor for advanced glycation end-product.

Keywords

  • Diabetic Nephropathy
  • Diabetic Retinopathy
  • Connective Tissue Growth Factor
  • Diabetic Macular Edema
  • Aldose Reductase Inhibitor

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-0-387-69737-6_20
  • Chapter length: 10 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   139.00
Price excludes VAT (USA)
  • ISBN: 978-0-387-69737-6
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   179.99
Price excludes VAT (USA)
Hardcover Book
USD   179.99
Price excludes VAT (USA)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86.

    Google Scholar 

  2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853.

    Google Scholar 

  3. Fagerudd J, Forsblom C, Pettersson-Fernholm K, Groop PH. Implementation of guidelines for the prevention of diabetic nephropathy. Diabetes Care 2004;27:803–804.

    PubMed  Google Scholar 

  4. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414:813–820.

    PubMed  CAS  Google Scholar 

  5. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999;344:109–116.

    PubMed  CAS  Google Scholar 

  6. Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 1994; 43:676–683.

    PubMed  CAS  Google Scholar 

  7. Monnier VM, Bautista O, Kenny D, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999;48:870–880.

    PubMed  CAS  Google Scholar 

  8. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications. Proc Natl Acad Sci U S A 1992; 89:12043–12047.

    PubMed  CAS  Google Scholar 

  9. Thomas MC, Tikellis C, Burns WM, et al. Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005;17:17.

    Google Scholar 

  10. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995;46:223–234.

    PubMed  CAS  Google Scholar 

  11. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 2003;21:3–12.

    PubMed  CAS  Google Scholar 

  12. Hogan M, Cerami A, Bucala R. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest 1992; 90:1110–1115.

    PubMed  CAS  Google Scholar 

  13. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404:787–790.

    PubMed  CAS  Google Scholar 

  14. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001;17:436–443.

    PubMed  CAS  Google Scholar 

  15. Kislinger T, Tanji N, Wendt T, et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2001;21:905–910.

    PubMed  CAS  Google Scholar 

  16. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006;114:597–605.

    PubMed  CAS  Google Scholar 

  17. Miyata T, Inagi R, Iida Y, et al. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest 1994;93:521–528.

    PubMed  CAS  Google Scholar 

  18. Rumble JR, Cooper ME, Soulis T, et al. Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products. J Clin Invest 1997;99:1016–1027.

    PubMed  CAS  Google Scholar 

  19. Kelly DJ, Gilbert RE, Cox AJ, Soulis T, Jerums G, Cooper ME. Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 2001;12:2098–2107.

    PubMed  CAS  Google Scholar 

  20. Twigg SM, Chen MM, Joly AH, et al. Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology 2001;142:1760–1769.

    PubMed  CAS  Google Scholar 

  21. Soulis T, Thallas V, Youssef S, et al. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 1997;40:619–628.

    PubMed  CAS  Google Scholar 

  22. Soulis T, Cooper ME, Sastra S, et al. Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats. Diabetologia 1997; 40:1141–1151.

    PubMed  CAS  Google Scholar 

  23. Degenhardt TP, Alderson NL, Arrington DD, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002;61:939–950.

    PubMed  CAS  Google Scholar 

  24. Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003;9:294–299.

    PubMed  CAS  Google Scholar 

  25. Cooper ME, Thallas V, Forbes J, et al. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia 2000;43:660–664.

    PubMed  CAS  Google Scholar 

  26. Forbes JM, Thallas V, Thomas MC, et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. Faseb J 2003;17:1762–1764.

    PubMed  CAS  Google Scholar 

  27. Edelstein D, Brownlee M. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 1992;41:26–29.

    PubMed  CAS  Google Scholar 

  28. Osicka TM, Yu Y, Panagiotopoulos S, et al. Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. Diabetes 2000;49:87–93.

    PubMed  CAS  Google Scholar 

  29. Rosca MG, Mustata TG, Kinter MT, et al. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol 2005; 289:F420–F430.

    PubMed  CAS  Google Scholar 

  30. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991;40:1328–1334.

    PubMed  CAS  Google Scholar 

  31. Edelstein D, Brownlee M. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia 1992;35:96–97.

    PubMed  CAS  Google Scholar 

  32. Lassila M, Seah KK, Allen TJ, et al. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 2004;15:2125–2138.

    PubMed  CAS  Google Scholar 

  33. Kern TS, Tang J, Mizutani M, et al. Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. Invest Ophthalmol Vis Sci 2000; 41:3972–3978.

    PubMed  CAS  Google Scholar 

  34. Cameron NE, Cotter MA, Dines K, Love A. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 1992;35:946–950.

    PubMed  CAS  Google Scholar 

  35. Birrell AM, Heffernan SJ, Ansselin AD, et al. Functional and structural abnormalities in the nerves of type I diabetic baboons: aminoguanidine treatment does not improve nerve function. Diabetologia 2000;43:110–116.

    PubMed  CAS  Google Scholar 

  36. Wada R, Sugo M, Nakano M, Yagihashi S. Only limited effects of aminoguanidine treatment on peripheral nerve function, (Na+, K+)-ATPase activity and thrombomodulin expression in streptozotocin-induced diabetic rats. Diabetologia 1999;42:743–747.

    PubMed  CAS  Google Scholar 

  37. Bolton WK, Cattran DC, Williams ME, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004;24:32–40.

    PubMed  CAS  Google Scholar 

  38. Tilton RG, Chang K, Hasan KS, et al. Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 1993; 42:221–232.

    PubMed  CAS  Google Scholar 

  39. Suji G, Sivakami S. DNA damage by free radical production by aminoguanidine. Ann N Y Acad Sci 2006;1067:191–199.

    PubMed  CAS  Google Scholar 

  40. Beisswenger P, Ruggiero-Lopez D. Metformin inhibition of glycation processes. Diabetes Metab 2003; 29:6S95–6S103.

    PubMed  CrossRef  CAS  Google Scholar 

  41. Gallo A, Ceolotto G, Pinton P, et al. Metformin prevents glucose-induced protein kinase C-beta2 activation in human umbilical vein endothelial cells through an antioxidant mechanism. Diabetes 2005; 54:1123–1131.

    PubMed  CAS  Google Scholar 

  42. Marchetti P, Del Guerra S, Marselli L, et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab 2004;89:5535–5541.

    PubMed  CAS  Google Scholar 

  43. Tsuchida K, Makita Z, Yamagishi S, et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 1999;42:579–588.

    PubMed  CAS  Google Scholar 

  44. Forbes JM, Soulis T, Thallas V, et al. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 2001;44:108–114.

    PubMed  CAS  Google Scholar 

  45. Wilkinson-Berka JL, Kelly DJ, Koerner SM, et al. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2) 27 rat. Diabetes 2002;51:3283–3289.

    PubMed  CAS  Google Scholar 

  46. Figarola JL, Scott S, Loera S, et al. LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats. Diabetologia 2003;46:1140–1152.

    PubMed  CAS  Google Scholar 

  47. Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J Biol Chem 2000;275:21177–21184.

    PubMed  CAS  Google Scholar 

  48. Voziyan PA, Metz TO, Baynes JW, Hudson BG. A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem 2002;277:3397–3403.

    PubMed  CAS  Google Scholar 

  49. Pedchenko VK, Chetyrkin SV, Chuang P, et al. Mechanism of perturbation of integrin-mediated cell-matrix interactions by reactive carbonyl compounds and its implication for pathogenesis of diabetic nephropathy. Diabetes 2005;54:2952–2960.

    PubMed  CAS  Google Scholar 

  50. Alderson NL, Chachich ME, Frizzell N, et al. Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat. Diabetologia 2004;47:1385–1395.

    PubMed  CAS  Google Scholar 

  51. Stitt A, Gardiner TA, Alderson NL, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002;51:2826–2832.

    PubMed  CAS  Google Scholar 

  52. Zheng F, Zeng YJ, Plati AR, et al. Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. Kidney Int 2006;70:507–514.

    PubMed  CAS  Google Scholar 

  53. Berrone E, Beltramo E, Solimine C, Ape AU, Porta M. Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem 2006; 281:9307–9313.

    PubMed  CAS  Google Scholar 

  54. Gadau S, Emanueli C, Van Linthout S, et al. Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. Diabetologia 2006;49:405–420.

    PubMed  CAS  Google Scholar 

  55. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003;52:2110–2120.

    PubMed  CAS  Google Scholar 

  56. Winkler G, Pal B, Nagybeganyi E, Ory I, Porochnavec M, Kempler P. Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy. Arzneimittelforschung 1999;49:220–224.

    PubMed  CAS  Google Scholar 

  57. Haupt E, Ledermann H, Kopcke W. Benfotiamine in the treatment of diabetic polyneuropathy–a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther 2005; 43:71–77.

    PubMed  CAS  Google Scholar 

  58. Stracke H, Lindemann A, Federlin K. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes 1996;104:311–316.

    PubMed  CAS  Google Scholar 

  59. Stirban A, Negrean M, Stratmann B, et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006;29:2064–2071.

    PubMed  CAS  Google Scholar 

  60. Vasan S, Zhang X, Kapurniotu A, et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996;382:275–278.

    PubMed  CAS  Google Scholar 

  61. Wolffenbuttel BH, Boulanger CM, Crijns FR, et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci U S A 1998;95:4630–4634.

    PubMed  CAS  Google Scholar 

  62. Candido R, Forbes JM, Thomas MC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003;92:785–792.

    PubMed  CAS  Google Scholar 

  63. Thallas-Bonke V, Lindschau C, Rizkalla B, et al. Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes 2004; 53:2921–2930.

    PubMed  CAS  Google Scholar 

  64. Forbes JM, Yee LT, Thallas V, et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004; 53:1813–1823.

    PubMed  CAS  Google Scholar 

  65. Susic D, Varagic J, Ahn J, Frohlich ED. Cardiovascular and renal effects of a collagen cross-link breaker (ALT 711) in adult and aged spontaneously hypertensive rats. Am J Hypertens 2004;17:328–333.

    PubMed  CAS  Google Scholar 

  66. Peppa M, Brem H, Cai W, et al. Prevention and Reversal of Diabetic Nephropathy in db/db Mice Treated with Alagebrium (ALT-711). Am J Nephrol 2006;26:430–436.

    PubMed  CAS  Google Scholar 

  67. Kass DA, Shapiro EP, Kawaguchi M, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001;104:1464–1470.

    PubMed  CAS  Google Scholar 

  68. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949–955.

    PubMed  CAS  Google Scholar 

  69. Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 1993;91:2155–2168.

    PubMed  CAS  Google Scholar 

  70. Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999;97:889–901.

    PubMed  CAS  Google Scholar 

  71. Kislinger T, Fu C, Huber B, et al. N(epsilon)- (carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999;274:31740–31749.

    PubMed  CAS  Google Scholar 

  72. Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998;4:1025–1031.

    PubMed  CAS  Google Scholar 

  73. Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003; 162:1123–1137.

    PubMed  CAS  Google Scholar 

  74. Sakaguchi T, Yan SF, Yan SD, et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003;111:959–972.

    PubMed  CAS  Google Scholar 

  75. Basta G, Sironi AM, Lazzerini G, et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006;91:4628–4634.

    PubMed  CAS  Google Scholar 

  76. Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006;49:2756–2762.

    PubMed  CAS  Google Scholar 

  77. Geroldi D, Falcone C, Emanuele E, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 2005;23:1725–1729.

    PubMed  CAS  Google Scholar 

  78. Srivastava SK, Ramana KV, Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev 2005;26:380–392.

    PubMed  CAS  Google Scholar 

  79. Sun W, Oates PJ, Coutcher JB, Gerhardinger C, Lorenzi M. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes 2006;55:2757–2762.

    PubMed  CAS  Google Scholar 

  80. Sorbinil Retinopathy Trial Research Group. The sorbinil retinopathy trial: neuropathy results. Neurology 1993;43:1141–1149.

    Google Scholar 

  81. Hamada Y, Nakamura J, Naruse K, et al. Epalrestat, an aldose reductase inhibitor, reduces the levels of Nepsilon-(carboxymethyl) lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care 2000;23:1539–1544.

    PubMed  CAS  Google Scholar 

  82. Bril V, Buchanan RA. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2006;29:68–72.

    PubMed  CAS  Google Scholar 

  83. Rask-Madsen C, King GL. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol 2005;25:487–496.

    PubMed  CAS  Google Scholar 

  84. Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997;100:115–126.

    PubMed  CAS  Google Scholar 

  85. Kapor-Drezgic J, Zhou X, Babazono T, Dlugosz JA, Hohman T, Whiteside C. Effect of high glucose on mesangial cell protein kinase C-delta and -epsilon is polyol pathway-dependent. J Am Soc Nephrol 1999;10:1193–1203.

    PubMed  CAS  Google Scholar 

  86. Goldberg HJ, Whiteside CI, Fantus IG. The hexosamine pathway regulates the plasminogen activator inhibitor-1 gene promoter and Sp1 transcriptional activation through protein kinase C-beta I and -delta. J Biol Chem 2002;277:33833–33841.

    PubMed  CAS  Google Scholar 

  87. Kang N, Alexander G, Park JK, et al. Differential expression of protein kinase C isoforms in streptozotocin-induced diabetic rats. Kidney Int 1999; 56:1737–1750.

    PubMed  CAS  Google Scholar 

  88. Shiba T, Inoguchi T, Sportsman JR, Heath WF, Bursell S, King GL. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol 1993;265:E783–E793.

    PubMed  CAS  Google Scholar 

  89. Inoguchi T, Sonta T, Tsubouchi H, et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P) H oxidase. J Am Soc Nephrol 2003;14:S227–S232.

    PubMed  CAS  Google Scholar 

  90. Xia L, Wang H, Goldberg HJ, Munk S, Fantus IG, Whiteside CI. Mesangial cell NADPH oxidase upregulation in high glucose is protein kinase C dependent and required for collagen IV expression. Am J Physiol Renal Physiol 2006;290: F345–F356.

    PubMed  CAS  Google Scholar 

  91. Tesfamariam B, Brown ML, Cohen RA. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest 1991; 87:1643–1648.

    PubMed  CAS  Google Scholar 

  92. Michell BJ, Chen Z, Tiganis T, et al. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem 2001; 276:17625–17628.

    PubMed  CAS  Google Scholar 

  93. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996;272:728–731.

    PubMed  CAS  Google Scholar 

  94. Suzuma K, Takahara N, Suzuma I, et al. Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci U S A 2002;99:721–726.

    PubMed  CAS  Google Scholar 

  95. Chakravarthy U, Hayes RG, Stitt AW, McAuley E, Archer DB. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes 1998;47:945–952.

    PubMed  CAS  Google Scholar 

  96. Cameron NE, Cotter MA, Jack AM, Basso MD, Hohman TC. Protein kinase C effects on nerve function, perfusion, Na(+), K(+)-ATPase activity and glutathione content in diabetic rats. Diabetologia 1999;42:1120–1130.

    PubMed  CAS  Google Scholar 

  97. Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest Ophthalmol Vis Sci 1998; 39:171–179.

    PubMed  CAS  Google Scholar 

  98. Cotter MA, Jack AM, Cameron NE. Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes. Clin Sci (Lond) 2002;103:311–321.

    CAS  Google Scholar 

  99. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005;54:2188–2197.

    Google Scholar 

  100. Strom C, Sander B, Klemp K, Aiello LP, Lund-Andersen H, Larsen M. Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. Invest Ophthalmol Vis Sci 2005;46:3855–3858.

    PubMed  Google Scholar 

  101. Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell SE. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 2006;47:86–92.

    PubMed  Google Scholar 

  102. Aiello LP, Davis MD, Girach A, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006;113:2221–2230.

    PubMed  Google Scholar 

  103. Vinik AI, Bril V, Kempler P, et al. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin Ther 2005;27:1164–1180.

    PubMed  CAS  Google Scholar 

  104. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005;28:2686–2690.

    PubMed  CAS  Google Scholar 

  105. Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Creager MA. Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res 2002;90:107–111.

    PubMed  CAS  Google Scholar 

  106. McGill JB, King GL, Berg PH, et al. Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin. Expert Opin Drug Saf 2006;5:835–845.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2007 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Soro-Paavonen, A., Cooper, M. (2007). Glycosylation Inhibitors, PKC Inhibitors and Related Interventions Against Complications. In: Mogensen, C.E. (eds) Pharmacotherapy of Diabetes: New Developments. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-69737-6_20

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-69737-6_20

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-69736-9

  • Online ISBN: 978-0-387-69737-6

  • eBook Packages: MedicineMedicine (R0)